Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2022 | Crenolanib plus 7+3 chemotherapy in adults with newly diagnosed FLT3-mutated AML.

Eunice Wang • 3 Jun 2022
ASCO 2022
Acute Myeloid Leukemia Leukemia Crenolanib Midostaurin

In this video, Eunice S. Wang, MD, Roswell Park Comprehensive Cancer Center, Buffalo, NY, presents long-term results of a Phase II study evaluating crenolanib, a potent FLT3 inhibitor, in patients with new diagnosed FLT3-mutated acute myeloid leukemia (AML). In combination with 7+3 induction and consolidation, crenolanib demonstrates high response rates in this patient population. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.

More from Eunice Wang

2:49
Results of a Phase I trial investigating CYNK-001, a placental NK-cell product, in patients with AML
Eunice Wang • 10 Dec 2023
1:30
A Phase I trial investigating a novel oral FLT3 inhibitor, BMF-500, in FLT3-mutant AML
Eunice Wang • 10 Dec 2023
3:03
The effect of BMI on survival outcomes in adolescents and young adults with AML
Eunice Wang • 10 Dec 2023
Novel targets, combinations & treatments
Eunice Wang et al. • 4 Sep 2023

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals